Celgene

Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018 Juno Therapeutics was acquired by Celgene for $9 billion.

Juno Therapeutics

Lenalidomide (trade name Revlimid) is a derivative of thalidomide introduced in 2004.  It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Along with several other drugs developed in recent years, lenalidomide has significantly improved overall survival in myeloma (which formerly carried a poor prognosis), although toxicity remains an issue for users. It costs $163,381 per year for the average patient.

Revlimid

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options.   There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma.   In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Celgene (CELG) and partner Acceleron obtain FDA approval for Reblozyl for the treatment of anemia in adult patients with beta thalassemia.

Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug

Biogen

Which stock wins in a head-to-head matchup between these two big biotechs?

Better Buy: Biogen vs. Celgene

Shares of Celgene Corp. [s:celg] rose 0.34% in afternoon trading after the U.S. Food and Drug Administration approved Reblozyl.

Celgene's rare disease drug gets FDA approval

CONMED

Edwards Lifesciences

Inmode Ltd

So smart investors are looking to cash in by eyeing key health care stocks.

Why You Should Keep An Eye On These 4 Leading Health Care Stocks

Celgene (CELG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Will Celgene (CELG) Gain on Rising Earnings Estimates?

Does Celgene (CELG) have what it takes to be a top stock pick for momentum investors? Let's find out.

Celgene (CELG) Is Up 3.16% in One Week: What You Should Know

Bio-Techne

CELG vs. TECH: Which Stock Is the Better Value Option?

Is  (CELG) Outperforming Other Medical Stocks This Year?

Is Celgene (CELG) Outperforming Other Medical Stocks This Year?

Celgene (CELG) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Why Celgene (CELG) Is a Great Growth Stock

Bristol-Myers

Celgene and Bristol-Myers Squibb up around 1%

2 Health Stocks With Gains Thursday

American Tower

Caterpillar

Enbridge

Mondelez

Stryker

According to the GuruFocus All-in-One Screener, the following stocks have outperformed the Standard & Poor's 500 Index over the past 12 months.

6 Guru Stocks Beating the Market.

Celgene (CELG) beats on earnings and revenues in the third quarter of 2019 on strong performance from Otezla and Revlimid.

Celgene (CELG) Q3 Earnings Beat, Otezla, Revlimid Sales Rise

Opdivo didn't turn in an impressive performance, but BMS' other drugs generated more than enough growth to top Wall Street's estimates.

Bristol-Myers Squibb Beats Expectations in Q3 as Its Celgene Acquisition Nears the Finish Line

Celgene (CELG) delivered earnings and revenue surprises of 9.52% and 1.72%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Celgene (CELG) Q3 Earnings and Revenues Top Estimates

Drug giants Bristol-Myers Squibb and Celgene topped third-quarter expectations Thursday, but shares slipped. In premarket trading on the stock market today, BMY stock skidded 1.4%.

Drug Giants Bristol-Myers, Celgene Top Third-Quarter Estimates

Celgene Corp. CELG, +0.82% said Thursday it had net income of $1.691 billion, or $2.32 a share, in the third quarter, up from $1.082 billion, or $1.50 a share, in the year-earlier period.

Celgene tops earnings estimates in latest quarter

There has been much debate whether it is best to hold shares in Celgene or Bristol-Myers.

Sell Celgene, Buy Bristol-Myers: Counting The Profits At The Halfway Mark

Celgene (CELG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Celgene (CELG)

Alexion Pharma

Amgen

Gilead Sciences

MannKind

The short interest data are out for the most recent settlement date, October 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Major Biotechs See Rising Tide in Short Interest (Oct 25)

Celgene (CELG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Celgene (CELG) Earnings Expected to Grow: Should You Buy?

Investors are looking forward to Revlimid's performance and updates on the acquisition by Bristol-Myers, when Celgene Corporation (CELG) reports Q3 results.

Factors Setting the Tone for Celgene (CELG) Q3 Earnings

Eli Lilly

Vertex Pharmaceuticals

Healthcare in particular is one such sector, with a number of large-cap biotechnology and pharmaceutical stocks enjoying fresh rallies.

5 Healthcare Stocks to Buy

Geron

Which stock wins between these two biotechs?

Better Buy: Geron Corporation vs. Celgene Corporation

Amarin Corporation Plc

These biotech stocks are great picks -- but for very different reasons.

3  Top Biotech Stocks to Buy Right Now

Celgene (CELG) closed at $99.30 in the latest trading session, marking a +0.46% move from the prior day.

News for Celgene Stock (CELG)